GlycoSeLect

About:

GlycoSeLect specializes in the development of technology to separate glycoproteins for biopharmaceutical product analysis & manufacture.

Website: http://www.glycoselect.com

Twitter/X: glycoselect

Top Investors: Enterprise Ireland, KBI Biopharma

Description:

GlycoSeLect specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs), enhanced tools for the analysis and selective purification of glycosylated biomolecules. RPLs have a broad spectrum of applications across the life sciences in: - Basic R&D – Glycobiology & Glycoproteomics. - Biomarker Discover & Biomedical Diagnostics. - The Biopharmaceutical Industry. - Vaccines - Cosmetics GlycoSeLect's Recombinant Prokaryotic Lectins (RPLs) present significant advantages over existing commercially available lectins products including: - Simplified, rapid & cost effective production through recombinant expression in Escherichia coli. - High purity & consistent performance. - Genetically enhanced glycan binding properties (specificity & affinity). - Scalable production facilitating utilization for large scale applications.